A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study

Steven C. Plaxe, John A. Blessing, George Olt, Nader Husseinzadah, Samuel S. Lentz, Koen DeGeest, Fidel A. Valea

Research output: Contribution to journalArticle

6 Scopus citations


Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

Original languageEnglish (US)
Pages (from-to)151-154
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Issue number2
StatePublished - Sep 12 2002



  • Cervical cancer
  • PZA
  • Pyrazoloacridine

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this